Immodulon brings together a team of scientific, drug development and medical experts, all committed to bringing to market first IMM‑101 and then other immunotherapies, so that as many patients as possible can benefit from the treatments. Immodulon is strongly protected and has one of the longest running research projects into the power of the immune system in fighting cancer.

Immodulon is led by a core management team of highly experienced practitioners and drug development experts, and supported by a Board of Directors with both medical & commercial expertise. Immodulon’s Scientific Advisory Board is made up of some of the leading names in immunology and oncology drug development.

Bio Elpida, the company-owned R&D and manufacturing capability in Lyon, France, provides specialist resources to advance the technology platform, including the potential to develop a variety of heat-killed mycobacterial products, as required to meet clinical and commercial needs. Immodulon is planning to expand production and development facilities by establishing a second laboratory outside France in a location to be decided.

Immodulon is an independent company, funded by private individual investors and with its own strategic control. It is philanthropic in its broader aims, committed to producing treatments that are widely affordable.

Board of Directors

The board brings together leaders in industry across the pharmaceutical, financial, legal and corporate advisory sectors, to advise on the corporate management and strategic direction of Immodulon. They share the philanthropic vison of the company.

Scientific Advisory Board

The board brings together some of the world’s most renowned scientists and practitioners to help Immodulon transform not only the way cancer is treated today, but also explore further how to harness the power of the immune system in treating disease.